Breaking News Instant updates and real-time market news.

AKAM

Akamai

$48.72

1.04 (2.18%)

, GNRC

Generac

$47.81

1.88 (4.09%)

10:27
10/02/17
10/02
10:27
10/02/17
10:27

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Akamai (AKAM) upgraded to Buy from Neutral at Guggenheim with analyst Robert Gutman citing valuation and raised its price target to $54 from $53. 2. Generac (GNRC) upgraded to Overweight from Sector Weight at KeyBanc with analyst Jeffrey Hammond saying the company is positioned to "meaningfully" re-accelerate growth and beat earnings expectations over the next 12-18 months. 3. Abercrombie & Fitch (ANF) upgraded to Hold from Sell at Argus with analysts John Eade and Annie Petrino saying new management is beginning to turn the operations around and shares have fallen to fallen for the past five years. 4. eGain (EGAN) upgraded to Buy from Hold at Craig-Hallum with analyst Jeff Van Rhee citing forward momentum building and compelling valuation. 5. AbbVie (ABBV) upgraded to Outperform from Market Perform at Leerink with analyst Geoffrey Porges saying he believes that there is still further upside as medium-and long-term estimates increase, and the company's multiple re-rates toward biopharmaceutical peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

AKAM

Akamai

$48.72

1.04 (2.18%)

GNRC

Generac

$47.81

1.88 (4.09%)

ANF

Abercrombie & Fitch

$14.27

-0.17 (-1.18%)

EGAN

eGain

$2.70

0.1 (3.85%)

ABBV

AbbVie

$89.92

1.0564 (1.19%)

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 07

    Dec

  • 11

    Dec

AKAM Akamai
$48.72

1.04 (2.18%)

09/05/17
09/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Owens-Illinois (OI) initiated with a Neutral at UBS. 2. Akamai (AKAM) initiated with a Neutral at Credit Suisse. 3. Zealand Pharma (ZEAL) was initiated with a Buy at Needham and Guggenheim while being initiated with an Overweight at Morgan Stanley. 4. YogaWorks (YOGA) was initiated with an Outperform at Cowen, an Overweight at Stephens, and a Buy at Roth Capital and Guggenheim. 5. Red Hat (RHT) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/17
GUGG
10/02/17
UPGRADE
Target $54
GUGG
Buy
Akamai upgraded to Buy from Neutral at Guggenheim
Guggenheim analyst Robert Gutman upgraded Akamai citing valuation and raised its price target to $54 from $53.
09/05/17
FBCO
09/05/17
INITIATION
Target $50
FBCO
Neutral
Akamai initiated with a Neutral at Credit Suisse
Credit Suisse analyst Brad Zelnick started Akamai with a Neutral rating and $50 price target saying that while he believes its leading position in Content Delivery Networks is convertible into something far more valuable, he opts for the sidelines until he gains comfort that expectations have bottomed.
09/26/17
JMPS
09/26/17
NO CHANGE
Target $64
JMPS
Outperform
Sentiment on Akamai has turned too negative, says JMP Securities
JMP Securities analyst Greg McDowell believes investor sentiment has turned too negative on Akamai (AKAM), as he believes the company still has a solid business and its future potential with OTT and security remain underappreciated. Widespread OTT adoption is nearer than investors think and Disney's (DIS) recent BAMTech deal and upcoming ESPN OTT launch could help Akamai stabilize or even grow media revenue, he tells investors. McDowell keeps an Outperform rating and $64 price target on Akamai shares.
GNRC Generac
$47.81

1.88 (4.09%)

10/02/17
KEYB
10/02/17
UPGRADE
Target $55
KEYB
Overweight
Generac upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Jeffrey Hammond upgraded Generac to Overweight saying the company is positioned to "meaningfully" re-accelerate growth and beat earnings expectations over the next 12-18 months. Extended power outages from Hurricane Iram should drive "meaningful" earnings upside, Hammond tells investors in a research note after spending time with Generac CEO Aaron Jagdfeld. The analyst sees further upside in the shares and set a $55 price target for Generac.
09/15/17
BOFA
09/15/17
UPGRADE
BOFA
Buy
Generac upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Ross Gilardi upgraded Generac to Buy and increased its price target to $50 from $45. Following recent hurricanes, millions remain without power which should drive demand for home standby generators, International EBITDA margins are expected to double in second half 2017 due to improved costs, and rental company demand has improved, which is good for Mobile Products, the analyst wrote in a note to investors.
09/07/17
09/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. RH (RH) upgraded to Buy from Neutral at Buckingham with analyst Kelly Halsor saying second quarter results changed is skeptical view of the turnaround story and he now expects a meaningful margin inflection in second half 2017 and beyond. 2. Generac (GNRC) upgraded to Neutral from Underperform at BofA/Merrill with analyst Ross Gilardi upgraded Generac ahead of Hurricane Irma and pending details into the company's investor day. 3. TJX (TJX) upgraded to Buy from Neutral at Northcoast analyst Nicholas Mitchell citing what he views as an attractive valuation, "plenty of runway" to grow sales through share capture and new store growth and his positive view of its new HomeSense concept. 4. Praxair (PX) upgraded to Positive from Neutral at Susquehanna with analyst Don Carson citing his pro-forma valuation following its merger with Linde. 5. PacWest Bancorp (PACW) upgraded to Buy from Neutral at DA Davidson with analyst Gary Tenner citing valuation following the recent pullback in the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/07/17
BOFA
09/07/17
UPGRADE
Target $34
BOFA
Neutral
Generac upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Ross Gilardi upgraded Generac to Neutral and increased its price target to $45 from $34 ahead if Hurricane Irma and pending details into today's investor day.
ANF Abercrombie & Fitch
$14.27

-0.17 (-1.18%)

08/25/17
08/25/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Starbucks (SBUX) upgraded to Outperform from Neutral at Wedbush by analyst Nick Setyan, telling investors he expects shares to move higher following an expected revision in long-term growth targets in October and an update on the China joint-venture acquisition. 2. Transocean (RIG), Rowan Companies (RDC), Noble Corp (NE), Diamond Offshore (DO) upgraded to Sector Perform from Underperform at RBC Capital and Oceaneering (OII) and Frank's International (FI) upgraded to Outperform from Sector Perform by RBC Capital's Kurt Hallead, who said there has been an improvement in the environment for offshore drillers. The analyst said contracted rig utilization has bottomed and there have been modest improvements with idle rigs going back to work. 3. Wayfair (W) upgraded to Buy from Hold at Stifel by analyst Scott Devitt, who said the company "has effectively addressed the key challenges" facing " a furniture, housewares, and home improvement eCommerce platform." The analyst thinks that the company's investments have created "a defensive moat" that will improve its competitive position and wide the gap between itself and competitors. 4. Abercrombie & Fitch (ANF) upgraded to Buy from Neutral at Citi by analyst Paul Lejuez who said that the company's Q2 results showed stabilization, particularly at Hollister, and the stock's valuation has become "too attractive to ignore." 5. Beacon Roofing (BECN) upgraded to Overweight from Sector Weight at KeyBanc and to Buy from Hold at Jefferies. Jefferies analyst Philip Ng said the recent pullback in shares creates a buying opportunity with its increased scale in roofing and new exposure to interior products. Ng said the Allied acquisition nearly doubles Beacon's size and reinforces its presence in roofing and diversifies into interior products, providing diversification, product growth in new areas, and new markets to pursue as a roil up story. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/31/17
08/31/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FMC Corporation (FMC) upgraded to Buy from Underperform at BofA/Merrill with analyst Steve Byrne double upgrading FMC following survey results that indicate ag sales are likely to increase 1-3% rather than decline 1-3%, as previously expected. 2. Owens Corning (OC) upgraded to Outperform from Market Perform at Wells Fargo with analyst Stephen East saying he sees an "inexpensive valuation" versus peers and has increased comfort in Owens' ability to achieve or surpass this year's targets. Hurricane Harvey is a boost to the company's roofing business, but its insulation replacement "may be the bigger winner," East tells investors. 3. ChannelAdvisor (ECOM) upgraded to Overweight from Equal-Weight at First Analysis with analyst Lawrence Berlin citing increased confidence in the company's ability to accelerate growth and hit its mid-teen growth targets after meeting with management. 4. Abercrombie & Fitch (ANF) upgraded to Sector Perform from Underperform at RBC Capital with analyst Brian Tunick saying a return to profitability in the second half of 2017 is more likely following Q2 results that suggest that turnaround efforts are yielding results faster than anticipated. 5. Transocean (RIG) upgraded to Overweight from Equalweight at Capital One with analyst Joseph Gibney saying the group is exhibiting some modest "green shoots" and sees upside to Transocean on a relative basis even in a long/measured recovery and some semblance of contracting pickup. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/17
ARGS
10/02/17
UPGRADE
ARGS
Hold
Abercrombie & Fitch upgraded to Hold from Sell at Argus
Argus analysts John Eade and Annie Petrino upgraded Abercrombie & Fitch to Hold saying new management is beginning to turn the operations around and shares have fallen to fallen for the past five years.
08/31/17
RBCM
08/31/17
UPGRADE
RBCM
Sector Perform
Abercrombie & Fitch upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital analyst Brian Tunick upgraded Abercrombie & Fitch to Sector Perform and raised its price target to $14 from $12 saying a return to profitability in the second half of 2017 is more likely following following Q2's (1%) comp and second half outlook for flat to slightly positive comps suggest that turnaround efforts are yielding results faster than anticipated. Tunick said improvements to the business and second half tailwinds are getting harder to ignore but adds long-term EBIT margin profile is a moving target.
EGAN eGain
$2.70

0.1 (3.85%)

11/10/16
LTCO
11/10/16
DOWNGRADE
Target $2.3
LTCO
Neutral
eGain downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Jon Hickman downgraded eGain to Neutral saying the company's Q1 results indicate its transition to a SaaS model is more disruptive to revenue growth than anticipated. The analyst lowered his price target for the shares to $2.30 from $3.75.
10/02/17
CHLM
10/02/17
UPGRADE
CHLM
Buy
eGain upgraded to Buy from Hold at Craig-Hallum
10/02/17
10/02/17
UPGRADE
Target $4

Buy
eGain upgraded to Buy at Craig-Hallum
As previously reported, Craig--Hallum analyst Jeff Van Rhee upgraded eGain to Buy from Hold, with a $4 price target, citing forward momentum building and compelling valuation.
ABBV AbbVie
$89.92

1.0564 (1.19%)

09/29/17
ARGS
09/29/17
NO CHANGE
ARGS
AbbVie price target raised to $110 after Humira settlement at Argus
Argus analyst David Toung says he has "greater confidence in the stability of Humira sales over the next five years" after AbbVie (ABBV) reached a settlement with Amgen (AMGN). The analyst does not expect Amgen to launch a biosimilar version of the drug in the U.S. until 2023. He raised his price target on the shares to $110 from $90 and keeps a Buy rating on the stock.
10/02/17
LEER
10/02/17
UPGRADE
LEER
Outperform
AbbVie upgraded to Outperform from Market Perform at Leerink
09/29/17
MSCO
09/29/17
NO CHANGE
Target $95
MSCO
Equal Weight
AbbVie price target raised to $95 after Humira settlement at Morgan Stanley
Morgan Stanley analyst David Risinger raised his Humira estimates in 2020 by 9% and sees U.S. biosimilar entry being delayed to August 2022 from January 2021 in the wake of AbbVie's (ABBV) Humira patent settlement with Amgen (AMGN). Given the model changes, he raised his price target on AbbVie to $95 from $70, though he keeps an Equal Weight rating on the stock as he sees only modest upside after the its recent outperformance.
10/02/17
10/02/17
UPGRADE
Target $106

Outperform
AbbVie upgraded to Outperform at Leerink
As previously reported, Leerink analyst Geoffrey Porges upgraded AbbVie to Outperform from Market Perform and raised his price target on the shares to $106 from $89. The analyst believes that there is still further upside as medium-and long-term estimates increase, and the company's multiple re-rates toward biopharmaceutical peers. Porges also sees opportunities for further positive estimate revisions as the company's late stage pipeline comes to fruition.

TODAY'S FREE FLY STORIES

HUBG

Hub Group

$49.00

-1.95 (-3.83%)

14:10
07/16/18
07/16
14:10
07/16/18
14:10
Options
Unusually large option print in Hub Group as shares slump »

Unusually large option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:10
07/16/18
07/16
14:10
07/16/18
14:10
General news
Fed's Kashkari worries about the flattening yield curve »

Fed's Kashkari…

JBHT

J.B. Hunt

$120.99

-0.78 (-0.64%)

14:08
07/16/18
07/16
14:08
07/16/18
14:08
Recommendations
J.B. Hunt analyst commentary  »

Loop says J.B. Hunt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

SYRS

Syros Pharmaceuticals

$12.35

(0.00%)

14:08
07/16/18
07/16
14:08
07/16/18
14:08
Conference/Events
Syros Pharmaceuticals to hold a key opinion leader meeting »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

, EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

14:02
07/16/18
07/16
14:02
07/16/18
14:02
Conference/Events
Rice Midstream to host special shareholder meeting »

Special Shareholder…

EQGP

EQT GP

$24.87

-0.25 (-1.00%)

EQM

EQT Midstream Partners

$54.90

0.49 (0.90%)

RMP

Rice Midstream

$18.16

0.16 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

CRSP

Crispr Therapeutics

$59.61

-6.13 (-9.32%)

14:01
07/16/18
07/16
14:01
07/16/18
14:01
Periodicals
Crispr Therapeutics tells CNBC does not use methods described in paper »

Crispr Therapeutics told…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$37.79

-0.22 (-0.58%)

14:00
07/16/18
07/16
14:00
07/16/18
14:00
Options
Bullish option play opened in Masco ahead of earnings »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

CRSP

Crispr Therapeutics

$59.09

-6.65 (-10.12%)

13:55
07/16/18
07/16
13:55
07/16/18
13:55
Options
Crispr Therapeutics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
07/16/18
07/16
13:50
07/16/18
13:50
General news
U.S. equities are up from earlier lows »

U.S. equities are up from…

ECA

Encana

$12.84

-0.4 (-3.02%)

13:45
07/16/18
07/16
13:45
07/16/18
13:45
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 09

    Oct

ADS

Alliance Data

$220.17

-23.32 (-9.58%)

13:44
07/16/18
07/16
13:44
07/16/18
13:44
Technical Analysis
Technical Take: Alliance Data comes off the lows of the day »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

CRM

Salesforce

$147.50

-0.18 (-0.12%)

13:39
07/16/18
07/16
13:39
07/16/18
13:39
Hot Stocks
Salesforce announces definitive agreement to acquire Datorama »

Salesforce has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 16

    Aug

YELP

Yelp

$40.33

0.54 (1.36%)

13:35
07/16/18
07/16
13:35
07/16/18
13:35
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBIX

Leading Brands

$1.62

-0.06 (-3.57%)

13:32
07/16/18
07/16
13:32
07/16/18
13:32
Hot Stocks
Leading Brands announces resolution of temporary non-compliance with Nasdaq rule »

Leading Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STM

STMicroelectronics

$22.84

0.2 (0.88%)

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Conference/Events
Stephens agricultural analyst to hold an analyst/industry conference call »

Agriculture, Chemicals,…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

, NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

13:23
07/16/18
07/16
13:23
07/16/18
13:23
Periodicals
Editas tells CNBC 'not specifically concerned about' Crisper study »

Editas Medicine (EDIT)…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$68.30

-0.33 (-0.48%)

13:19
07/16/18
07/16
13:19
07/16/18
13:19
Periodicals
CVS apologizes after store managers call police on black customer, AP says »

CVS Health is apologizing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/16/18
07/16
13:17
07/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/16/18
07/16
13:16
07/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGI

Pattern Energy

$17.84

0.75 (4.39%)

13:10
07/16/18
07/16
13:10
07/16/18
13:10
Options
Change of sentiment in Pattern Energy »

Change of sentiment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
07/16/18
07/16
13:05
07/16/18
13:05
Conference/Events
The Brookings Institution to hold a conference »

7th Annual Municipal…

C

Citi

$69.22

2.22 (3.31%)

13:04
07/16/18
07/16
13:04
07/16/18
13:04
Hot Stocks
Citi reports June credit loss 2.60% vs. 2.78% last month »

Reports June 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

ORMP

Oramed

$5.89

-0.08 (-1.34%)

13:02
07/16/18
07/16
13:02
07/16/18
13:02
Downgrade
Oramed rating change  »

B. Riley FBR downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$69.21

0.03 (0.04%)

13:01
07/16/18
07/16
13:01
07/16/18
13:01
Hot Stocks
Quidel receives FDA clearance to market Solana Bordetella Complete Assay »

Quidel announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.